DNV, an EU Notified Body for the In Vitro Diagnostic Medical Devices Regulation (IVDR), announced on Wednesday that it has issued an IVDR certificate to China-based FAMID Biomedical Technology (Tianjin) Co Ltd for its diagnostic test designed to support the early detection of cervical cancer.
According to DNV, the certification was completed in just six months, following assessment of the manufacturer's quality management system, clinical evidence and technical documentation.
FAMID Biomedical's newly certified E7 Oncoprotein Rapid Test Kit, classified as a Class C in vitro diagnostic medical device under the IVDR, is designed as an aid in the diagnosis of cervical epithelial cell lesions through the detection of HPV E7 oncoprotein in cervical cell samples. The product is intended for both professional laboratory use and self-testing.
Asker Healthcare Group acquires Estonia's Teresa OÜ
Abbott's Amulet 360 shows high LAA closure rates and low stroke incidence at one year
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Abbott reports 30-day results from clinical trial of SonicForce Coronary IVL System
Edwards Lifesciences wins FDA approval for PASCAL Precision tricuspid repair system
Abbott secures CE Mark for Cologuard Plus in Europe
VibroSense Dynamics secures Thai regulatory approval for VibroSense Meter II
SciBase technology selected as primary endpoint in NIH-led skin exposure study
TWINBIRD launches portable freezer targeting dry-ice-free research cold chains
Urolution Medical secures FDA clearance for OpenFlo urinary catheter
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay
Okami Medical receives FDA approval for expanded indication of LOBO Vascular Occluder